At the Longevity Summit Dublin 2024, Caitlin Lewis from the LEV Foundation presented their pioneering work on combining multiple interventions to target ageing comprehensively. The foundation's flagship study, Robust Mass Rejuvenation (RMR), is designed to test the effectiveness of therapies such as Rapamycin, young hematopoietic stem cells, TERT gene therapy, and a senolytic. Early findings suggest that combining interventions may yield better outcomes than single therapies. The LEV Foundation is committed to advancing life-extending treatments and making these breakthroughs accessible to the broader public.

Key Points:

• Introduction to LEV Foundation's Flagship Program: Robust Mass Rejuvenation (RMR) : Caitlin Lewis, Director of Pipeline and Strategy at LEV Foundation, discussed their flagship program aimed at developing and testing combinations of interventions for life extension, targeting multiple aspects of ageing rather than just individual components.
• Rationale Behind Multi-Intervention Strategies: The foundation’s focus is to develop comprehensive treatments for ageing by combining various therapies. The goal is not just to prolong life but to prove to policymakers and the public that ageing can be reversed and is more malleable than traditionally thought.
• Selection Criteria for Study: Key selection criteria for interventions include studies on normal ageing mice (not accelerated models), interventions initiated after middle age, and those showing both mean and maximum lifespan extension. Four interventions—Rapamycin, Young Hematopoietic Stem Cells, TERT Gene Therapy, and a Senolytic—were chosen for testing.
• Complex Study Design: The study includes several groups with single and combined treatments to understand how different therapies interact. It is both longitudinal and cross-sectional, examining lifespan and health outcomes in ageing mice.
• Preliminary Observations and Sexual Dimorphism: Early data show that combinations of treatments are outperforming single interventions, though Rapamycin remains a strong benchmark. The study also highlights notable sex differences in response to therapies, emphasizing the need to include both male and female subjects.
• Future Directions and Open Data: LEV Foundation plans to continue the study and make their data openly available. They aim to add more variables, such as exercise wheels for mice, in future iterations of the study, and to further test different dosages and combinations of therapies to optimize outcomes.